- Home
- COCH vs ELUT Comparison
COCH vs ELUT Comparison
Compare COCH & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COCH | ELUT |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 42.5M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | COCH | ELUT |
|---|---|---|
| Price | $0.70 | $0.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.00 | $6.00 |
| AVG Volume (30 Days) | ★ 97.0K | 56.0K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.45 | ★ 146.77 |
| EPS | ★ N/A | N/A |
| Revenue | $241,000.00 | ★ $12,293,000.00 |
| Revenue This Year | $1.58 | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.11 | N/A |
| 52 Week Low | $0.36 | $0.50 |
| 52 Week High | $1.89 | $2.38 |
Technical Indicators
Market Signals| Indicator | COCH | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 49.02 |
| Support Level | $0.63 | $0.84 |
| Resistance Level | $0.77 | $1.04 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 46.86 | 51.53 |
Price Performance
Historical ComparisonAbout COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
About ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.